The VeriStrat specimen collection and shipping kit from Biodesix, Boulder, Colo, facilitates specimen collection for the noninvasive, blood-based VeriStrat protein diagnostic to help guide therapy decisions for non-small cell lung cancer patients.
Read More
The National Cancer Institute has awarded Insight Genetics a $1.5 million Phase II continuation of its SBIR contract for developing a companion diagnostic to assess patient resistance to therapies for non-small cell lung cancer.
Read More
Test accurately identifies which patients may need postsurgical chemotherapy.
Read More
Findings could help identify patients most likely to benefit from lung-sparing surgery.
Read More
The test uses a panel of tumor antigens to diagnose autoantibodies produced by the patient’s immune system when lung cancer is present.
Read More